Dimensional Fund Advisors LP Purchases 26,253 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Dimensional Fund Advisors LP increased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 6.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 436,460 shares of the biopharmaceutical company’s stock after purchasing an additional 26,253 shares during the period. Dimensional Fund Advisors LP’s holdings in Xenon Pharmaceuticals were worth $17,011,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Parallel Advisors LLC increased its stake in Xenon Pharmaceuticals by 51.2% in the 4th quarter. Parallel Advisors LLC now owns 1,125 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 381 shares in the last quarter. California State Teachers Retirement System raised its stake in Xenon Pharmaceuticals by 0.9% during the 1st quarter. California State Teachers Retirement System now owns 56,477 shares of the biopharmaceutical company’s stock valued at $2,431,000 after purchasing an additional 490 shares during the period. ProShare Advisors LLC lifted its holdings in Xenon Pharmaceuticals by 12.0% in the 1st quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 565 shares in the last quarter. Arizona State Retirement System boosted its stake in Xenon Pharmaceuticals by 4.0% in the 2nd quarter. Arizona State Retirement System now owns 17,949 shares of the biopharmaceutical company’s stock worth $700,000 after purchasing an additional 688 shares during the period. Finally, Envestnet Asset Management Inc. grew its holdings in Xenon Pharmaceuticals by 1.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 48,946 shares of the biopharmaceutical company’s stock valued at $1,908,000 after buying an additional 769 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Wedbush decreased their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. HC Wainwright started coverage on Xenon Pharmaceuticals in a report on Tuesday. They issued a “buy” rating and a $53.00 target price on the stock. Finally, Needham & Company LLC dropped their price target on Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $58.20.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $40.73 on Friday. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -15.03 and a beta of 1.25. The business has a 50 day simple moving average of $40.11 and a 200-day simple moving average of $40.29. Xenon Pharmaceuticals Inc. has a 1 year low of $27.99 and a 1 year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same period in the prior year, the firm earned ($0.72) EPS. As a group, analysts expect that Xenon Pharmaceuticals Inc. will post -3.14 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.